Barclays
OPNT

Barclays’s Opiant Pharmaceuticals, Inc. Common Stock OPNT Stock Holding History

Barclays’s Portfolio OPNT Stock Details OPNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-30
Closed – – 6986
2019
Q3 		$0 Buy
+30
New +$418 ﹤0.01% 7283
2018
Q2 		– Sell
-4
Closed – – 7407
2018
Q1 		$0 Buy
+4
New +$86 ﹤0.01% 7438

Other funds holding OPNT

SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
FM
Fondren Management Houston, Texas $16.9M AUM 5.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PCM
Perritt Capital Management Chicago, Illinois $59.8M AUM 26.94% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WCM
Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return
AG
Advisor Group Phoenix, Arizona $14.5B AUM 24.86% 1-Year Est. Return
ASN
Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return

Barclays's OPNT Position: Q4 2019 in Review

Barclays sold out of Opiant Pharmaceuticals, Inc. Common Stock (OPNT) in Q4 2019, closing a stake of 30 shares.

Barclays first reported a position in OPNT in Q1 2018 and held it in 2 quarters. The position peaked at $0 in Q3 2019. 28 funds tracked by Wall St. Rank hold OPNT as of Q4 2019.

  • Barclays reported no remaining Opiant Pharmaceuticals, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
  • Barclays sold 30 Opiant Pharmaceuticals, Inc. Common Stock shares in Q4 2019.
  • Barclays first reported a position in Opiant Pharmaceuticals, Inc. Common Stock in Q1 2018 and held it in 2 quarters.
  • Barclays's Opiant Pharmaceuticals, Inc. Common Stock position peaked at $0 in Q3 2019.
  • 28 funds tracked by Wall St. Rank held Opiant Pharmaceuticals, Inc. Common Stock as of Q4 2019.

Based on Barclays's 13F filing for Q4 2019, filed 10 Feb 2020.